Filtered By:
Drug: Prozac
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 128 results found since Jan 2013.

Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania
Post-stroke fluoxetine trials are primarily conducted in high-income countries. We characterize post-ischemic stroke depression in fluoxetine-treated and -untreated study participants in urban Tanzania.
Source: Journal of Stroke and Cerebrovascular Diseases - November 2, 2021 Category: Neurology Authors: Dylan R. Rice, Kigocha Okeng'o, Emmanuel Massawe, Seif Ismail, Notburga A. Mworia, Faraja Chiwanga, Boniface Kapina, Michael Wasserman, Farrah J. Mateen Source Type: research

Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China
We investigated the effects of fluoxetine on the short-term and long-term neural functional prognoses after ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - January 25, 2016 Category: Neurology Authors: Yi-Tao He, Bing-Shan Tang, Zhi-Li Cai, Si-Ling Zeng, Xin Jiang, Yi Guo Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS: We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings. PMID: 31769878 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 25, 2019 Category: General Medicine Authors: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Podcast: Selective serotonin reuptake inhibitors for stroke recovery
Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.Stroke is a common cause of disability in the community. Although there have been major advances in the care of stroke patients over the last few years, many survivors are still left with physical disability, such as weakn...
Source: Cochrane News and Events - February 26, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research

Pharmacological interventions and rehabilitation approach for enhancing brain self-repair and stroke recovery.
Abstract Neuroplasticity is a natural process occurring in the brain for entire life. Stroke is the leading cause of long term disability and huge medical and financial problem throughout the world. Research conducted over the past decade focused mainly on neuroprotection in the acute phase of stroke while very little studies targets chronic stage. Recovery after stroke depends on the ability of our brain to reestablish structural and functional organization of neurovascular networks. Combining adjuvant therapies and drugs may enhance the repair processes and restore impaired brain functions. Currently, there are ...
Source: Current Neuropharmacology - July 24, 2019 Category: Drugs & Pharmacology Authors: Szelenberger R, Kostka J, Saluk-Bijak J, Miller E Tags: Curr Neuropharmacol Source Type: research

Interventions for post-stroke fatigue.
CONCLUSIONS: There was insufficient evidence on the efficacy of any intervention to treat or prevent fatigue after stroke. Trials to date have been small and heterogeneous, and some have had a high risk of bias. Some of the interventions described were feasible in people with stroke, but their efficacy should be investigated in RCTs with a more robust study design and adequate sample sizes. PMID: 26133313 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 2, 2015 Category: Journals (General) Authors: Wu S, Kutlubaev MA, Chun HY, Cowey E, Pollock A, Macleod MR, Dennis M, Keane E, Sharpe M, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials
DiscussionIf fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.Trial registrationFOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011). EFFECTS: ISRCTN13020412 (19/12/2014).
Source: Trials - August 20, 2015 Category: Journals (General) Authors: Gillian MeadMaree HackettErik LundströmVeronica MurrayGraeme HankeyMartin Dennis Source Type: research

A commonly-used antidepressant doesn ' t improve recovery after stroke
The antidepressant fluoxetine works no better than placebo to reduce disability after a stroke, lowering hopes that had been raised by other smaller studies. After a six month trial including more than 3,000 adult stroke patients recruited at 103 UK hospitals, researchers concluded that fluoxetine should not be used to promote recovery from stroke-related disability, or routinely prescribed to prevent depression after stroke. Several smaller studies and animal trials had found promising results from the use of fluoxetine after stroke. However, this trial of fluoxetine 20mg daily for six months found no improvement in funct...
Source: Current Awareness Service for Health (CASH) - February 18, 2019 Category: Consumer Health News Source Type: news

Fluoxetine or Venlafaxine for Early Post Stroke Depression
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.
Source: Neurology India - December 19, 2022 Category: Neurology Authors: Vivek K Nambiar J Parvathy Tania M Philip K Abhijith S Sreeni Naveen K Panicker Amrutha V Ajai TS Dhanya Source Type: research

Neuroplasticity and behavioral effects of  fluoxetine after experimental stroke.
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. Restor Neurol Neurosci. 2017 Aug 24;: Authors: Sun Y, Sun X, Qu H, Zhao S, Xiao T, Zhao C Abstract The brain can undergo self-repair and has the ability to compensate for functions lost after a stroke. The plasticity of the ischemic brain is influenced by several factors including aging and pharmacotherapy. Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin. In clinical practice, fluoxetine alleviates the symptoms of post-stroke depre...
Source: Restorative Neurology and Neuroscience - September 1, 2017 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
CONCLUSION: There was no significant difference between citalopram and fluoxetine in facilitating post-stroke motor recovery in ischemic stroke patients. However, compared with a placebo, both drugs improved post-stroke motor function. PMID: 29783900 [PubMed - as supplied by publisher]
Source: Clinical Rehabilitation - May 1, 2018 Category: Rehabilitation Authors: Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E Tags: Clin Rehabil Source Type: research

Pharmacological Enhancement of Stroke Recovery
AbstractPurpose of ReviewThis review aims to discuss the recent literature relating to drugs for stroke recovery and to identify some of the challenges in conducting translational research for stroke recovery.Recent FindingsAdvances in our understanding of neural repair mechanisms in pre-clinical stroke models have provided insights into potential targets for drugs that enhance the repair/recovery process. Few drugs that act on serotonergic and dopaminergic systems have been tested in humans with mixed results. The FOCUS trial, a phase III study of early administration of fluoxetine for stroke recovery, failed to replicate...
Source: Current Neurology and Neuroscience Reports - May 29, 2019 Category: Neuroscience Source Type: research

Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial.
CONCLUSIONS AND CLINICAL IMPLICATIONS: Consistent with other trials based on the FOCUS protocol, fluoxetine did not improve motor recovery or general stroke outcome at six and 12 months in the Polish cohort studied. However, patients receiving fluoxetine required therapy with additional antidepressant medication less frequently. PMID: 33373036 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - December 29, 2020 Category: Neurology Authors: Bembenek JP, Niewada M, Kłysz B, Mazur A, Kurczych K, Głuszkiewicz M, Członkowska A Tags: Neurol Neurochir Pol Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
CONCLUSIONS: There is high-quality evidence that SSRIs do not make a difference to disability or independence after stroke compared to placebo or usual care, reduced the risk of future depression, increased bone fractures and probably increased seizure risk.PMID:34780067 | DOI:10.1002/14651858.CD009286.pub4
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Lynn A Legg Ann-Sofie Rudberg Xing Hua Simiao Wu Maree L Hackett Russel Tilney Linnea Lindgren Mansur A Kutlubaev Cheng-Fang Hsieh Amanda J Barugh Graeme J Hankey Erik Lundstr öm Martin Dennis Gillian E Mead Source Type: research